- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05798897
Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma (APOLLO)
A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen-Specific T Cells (MT-601) Administered to Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL [APOLLO])
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Gerald Garrett
- Phone Number: 713.400.6400
- Email: ggarrett@markertherapeutics.com
Study Contact Backup
- Name: Mythili Koneru, MD, PhD
- Phone Number: 713.400.6400
- Email: mkoneru@markertherapeutics.com
Study Locations
-
-
California
-
Duarte, California, United States, 91010
- Recruiting
- City of Hope
-
Principal Investigator:
- Geoffrey Shouse, DO, PhD
-
Contact:
- Geoffrey Shouse, DO, PhD
- Phone Number: 626-218-2405
- Email: gshouse@coh.org
-
-
Colorado
-
Denver, Colorado, United States, 80218
- Recruiting
- Colorado Blood Cancer Institute (Sarah Cannon)
-
Contact:
- Luke Mountjoy, DO
- Phone Number: 720-754-4800
- Email: Luke.Mountjoy@HealthONEcares.com
-
Principal Investigator:
- Luke Mountjoy, DO
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Recruiting
- Tennessee Oncology PLLC
-
Contact:
- Ian Flinn, MD, PhD
- Phone Number: 615-329-7274
- Email: iflinn@tnonc.com
-
Principal Investigator:
- Ian Flynn, MD, PhD
-
-
Texas
-
Austin, Texas, United States, 78704
- Recruiting
- Sarah Cannon Research Institute at St. David's South Austin
-
Contact:
- Aravind Ramakrishnan, MD
- Phone Number: 512-816-8600
- Email: Aravind.Ramakrishnan@hcahealthcare.com
-
Principal Investigator:
- Aravind Ramakrishnan, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All applicable inclusion and exclusion criteria must be met at Screening and at Baseline (re-assessment of eligibility within 14 days prior to group assignment).
Patients are eligible to be included in the study only if all of the following criteria apply and the patient, in the judgement of the Investigator, is an appropriate candidate for experimental therapy:
- Cytologically or histologically confirmed diagnosis of Non-Hodgkin Lymphoma (in any subtype where CD19+ T cell therapy is approved, e.g., DLBCL, MCL, FL)
- Relapsed or refractory to CD19+ CAR T cell therapy or ineligible for CD19+ CAR T cell therapy (includes patients whose BOR of SD following CD19+ CAR T cell therapy).
- Patients who have had only BOR of PR to CD19+ CAR T cell therapy may also enroll
- Are ≥18 years of age prior to administration of MT-601
- Patients must have patient-derived cells available to make MT-601
- Karnofsky/Lansky score of ≥70 or performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale
- Life expectancy ≥12 weeks
Adequate blood, liver, and renal function
- Blood: Hemoglobin ≥7.0 g/dL (can be transfused)
- Liver: Bilirubin ≤1.5X upper limit of normal (ULN) (exception of bilirubin elevation due to Gilbert's syndrome); aspartate aminotransferase ≤3X ULN
- Renal: Serum creatinine ≤2X ULN or measured or calculated creatinine clearance ≥30mL/min
- Sexually active patients must be willing to utilize one of the highly effective birth control methods or practice complete abstinence starting from Screening for T cell infusion until 6 months after the last T cell infusion. Male patients who are sexually active must agree to use a condom during this period
- At least 4 half-lives or 1 week has passed after administration of prior therapy or bridging therapy
- Dose escalation defined as patients whose prior treatment course does not meet precise eligibility criteria but may still be approved upon review by the Sponsor
Exclusion Criteria:
Patients are excluded from the study if any of the following criteria apply:
- Clinically significant or severely symptomatic intercurrent infection (e.g. patients with uncontrolled HIV infection or have active HBV/HCV infection)
- Pregnant or lactating
- Any other issue which, in the opinion of the treating physician, would make the patient ineligible for the study
- Taking systemic corticosteroids (exception: physiological doses of steroids allowed)
- Autologous or allogeneic HSCT within 1 month
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single Arm Study
Single arm study evaluating MT-601 investigational product at 200 million cells and 400 million cells per dose
|
Multi-antigen specific CD4+ andCD8+ T cells
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose Escalation
Time Frame: After 3 or 6 patients in each dose cohort have been treated with MT-601 and have had the opportunity to be followed for 28 days.
|
To assess safety and tolerability of escalating doses of MT-601 by the number of participants with MT-601 Dose Limiting Toxicities (DLTs) and Safety events (including but not limited to): treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), deaths, and clinical laboratory abnormalities per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0)
|
After 3 or 6 patients in each dose cohort have been treated with MT-601 and have had the opportunity to be followed for 28 days.
|
Dose Expansion (ORR)
Time Frame: 12 months after the last patient treated in the Dose Expansion portion of the study receiving the first dose of MT-601.
|
To assess anti-tumor activity of MT-601 based on Lugano Classification by the following endpoints:
|
12 months after the last patient treated in the Dose Expansion portion of the study receiving the first dose of MT-601.
|
Dose Expansion (DOR)
Time Frame: 12 months after the last patient treated in the Dose Expansion portion of the study receiving the first dose of MT-601.
|
To assess anti-tumor activity of MT-601 based on Lugano Classification by the following endpoints:
|
12 months after the last patient treated in the Dose Expansion portion of the study receiving the first dose of MT-601.
|
Dose Expansion (CR)
Time Frame: 12 months after the last patient treated in the Dose Expansion portion of the study receiving the first dose of MT-601.
|
To assess anti-tumor activity of MT-601 based on Lugano Classification by the following endpoints:
|
12 months after the last patient treated in the Dose Expansion portion of the study receiving the first dose of MT-601.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MRKR-22-601-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non Hodgkin Lymphoma
-
Caribou Biosciences, Inc.RecruitingLymphoma | Lymphoma, Non-Hodgkin | B Cell Lymphoma | Non Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma | B Cell Non-Hodgkin's LymphomaUnited States, Australia, Israel
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin LymphomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
National Cancer Institute (NCI)RecruitingRefractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Recurrent Primary Cutaneous... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRefractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Hematopoietic Cell Transplantation RecipientUnited States
-
Mayo ClinicNot yet recruitingIndolent B-Cell Non-Hodgkin Lymphoma | Recurrent Indolent Non-Hodgkin Lymphoma | Refractory Indolent Non-Hodgkin Lymphoma | Recurrent Indolent B-Cell Non-Hodgkin Lymphoma | Refractory Indolent B-Cell Non-Hodgkin LymphomaUnited States
-
University of WashingtonRecruitingRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin LymphomaUnited States
-
Chongqing Precision Biotech Co., LtdRecruitingNon Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Relapsed Non-Hodgkin LymphomaChina
-
Estrella Biopharma, Inc.Eureka Therapeutics Inc.Not yet recruitingLymphoma | Lymphoma, Non-Hodgkin | Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | CNS Lymphoma | Lymphomas Non-Hodgkin's B-Cell | Relapsed Non-Hodgkin Lymphoma | Lymphoma, Non-Hodgkins | Large B-Cell Lymphoma and other conditions
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingRefractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma | Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma | Refractory Cutaneous T-Cell Non-Hodgkin LymphomaUnited States
Clinical Trials on MT-601
-
Joanne Kurtzberg, MDAldagenWithdrawnLysosomal Storage Diseases | Inborn Errors of MetabolismUnited States
-
ADC Therapeutics S.A.TerminatedAdvanced Solid TumorsUnited States
-
C.B. Fleet Company, Inc.CompletedBowel Cleansing Prior to ColonoscopyUnited States
-
National Institute of Allergy and Infectious Diseases...Active, not recruiting
-
Motric BioRecruitingStroke | Multiple Sclerosis | Cerebral Palsy | Spinal Cord Injuries | Dystonia | Muscle Spasticity | Hereditary Spastic Paraplegia | Hypertonia, MuscleUnited States
-
TransMolecularUnknownAstrocytoma | Glioblastoma Multiforme | Malignant Glioma | GBM | OligodendrogliomaUnited States
-
TransMolecularCompletedGlioma | Brain NeoplasmUnited States
-
Mitsubishi Tanabe Pharma CorporationCompletedDiabetic NephropathyJapan
-
Erasca, Inc.Active, not recruitingAdvanced or Metastatic Solid TumorsUnited States
-
Mitsubishi Tanabe Pharma America Inc.CompletedMenopause Hot FlashesUnited States